ArQule’s Lead Anti-Cancer Compound ARQ 501

• Phase I commenced Sept. 2003

• “First-in-class” small molecule cancer drug

• New mechanism

• Highly selective

• Broad spectrum

• Large therapeutic index

E2F

Pathway

Previous slide

Next slide

Back to first slide

View graphic version